Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism [14]

Nephrology Dialysis Transplantation

Volumn 22, Issue 7, 2007, Pages 2102-2103

  Jean, Guillaume ^a   Chazot, Charles ^a   Charra, Bernard ^a  

^a Centre de Rein Artificiel de Tassin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CINACALCET; COLLAGEN TYPE 1; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER;

ADULT; AGED; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHEMOLUMINESCENCE; CLINICAL ARTICLE; COMORBIDITY; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; LETTER; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; TABLET FORMULATION; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; WEANING;

ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; RENAL DIALYSIS;

EID: 34547843557     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm172     Document Type: Letter

References (4)

1. Goodman WG. Calcimimetic agents for the treatment of secondary hyperparathyroidism. Seminars in Nephrology 2004; 24: 460-463
2. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyper-parathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
3. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCI. Kidney Int 2005; 67: 760-771
4. Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCI. Nephrol Dial Transplant 2005; 20: 2186-2193